Last reviewed · How we verify
NCT05908799
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
trial testing Pembrolizumab + Pemetrexed-Platinum in Non-small Cell Lung Cancer in 1,854 participants. Completed in 31 August 2023.
31 August 2023
Quick facts
| Lead sponsor | Aetion, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,854 |
| Start date | 5 June 2023 |
| Primary completion | 31 August 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pembrolizumab + Pemetrexed-Platinum — full drug profile →
- Pemetrexed-Platinum
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Metastatic Lung Cancer — all drugs for Metastatic Lung Cancer →
Sponsor
Aetion, Inc. — full company profile →
Who can join
Eligibility, any sex, with Non-small Cell Lung Cancer or Metastatic Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators are building an empirical evidence base supporting the utility of real-world data through the emulation of randomized controlled trials in the oncology setting. The purpose of this work is to demonstrate whether real-world evidence studies can provide reliable conclusions on treatment effectiveness to inform further applications of real-world data in pharmaceutical product label expansion, post-marketing safety, and other purposes that are complementary to RCTs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05908799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Aetion, Inc. trials
Trials by the same sponsor.
- NCT05638932 — Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments · completed
- NCT04926571 — Dexamethasone and COVID-19 Inpatient Mortality · completed
- NCT06607601 — CARE Initiative: Real-world Emulation of the PALOMA-2 Trial · completed
- NCT06607393 — CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] · completed
- NCT06585189 — CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05908799 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aetion, Inc.
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05908799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing